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A B S T R A C T
Background
Asthma guidelines aim to guide health practitioners to optimise treatment for patients so as tominimise symptoms, improve or maintain
good lung function, and prevent acute exacerbations or flare-ups. The principle of asthma guidelines is based on a step-up or step-
down regimen of asthma medications to maximise good health outcomes using minimum medications. Asthma maintenance therapies
reduce airway inflammation that is usually eosinophilic. Tailoring asthma medications in accordance with airway eosinophilic levels
may improve asthma outcomes such as indices of control or reduce exacerbations or both. Fractional exhaled nitric oxide (FeNO)
is a marker of eosinophilic inflammation, and as it is easy to measure, has an advantage over other measurements of eosinophilic
inflammation (for example sputum eosinophils).
Objectives
To evaluate the efficacy of tailoring asthma interventions based on exhaled nitric oxide (FeNO), in comparison to not using FeNO, that
is management based on clinical symptoms (with or without spirometry/peak flow) or asthma guidelines or both, for asthma-related
outcomes in adults.
Search methods
We searched the Cochrane Airways Group Specialised Register of Trials, the Cochrane Central Register of Controlled Trials (CEN-
TRAL), MEDLINE, EMBASE, and reference lists of articles. The last searches were undertaken in June 2016.
Selection criteria
All randomised controlled trials (RCTs) comparing adjustment of asthma medications based on exhaled nitric oxide levels compared
to not using FeNO, that is management based on clinical symptoms (with or without spirometry/peak flow) or asthma guidelines or
both.
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Data collection and analysis
We reviewed results of searches against predetermined criteria for inclusion.We independently selected relevant studies in duplicate. Two
review authors independently assessed trial quality and extracted data. We contacted study authors for further information, receiving
responses from four.
Main results
We included seven adult studies; these studies differed in a variety of ways including definition of asthma exacerbations, FeNO cutoff
levels used (15 to 35 ppb), the way in which FeNO was used to adjust therapy, and duration of study (4 to 12 months). Of 1700
randomised participants, 1546 completed the trials. The mean ages of the participants ranged from 28 to 54 years old. The inclusion
criteria for the participants in each study varied, but all had a diagnosis of asthma and required asthma medications. In the meta-
analysis, there was a significant difference in the primary outcome of asthma exacerbations between the groups, favouring the FeNO
group. The number of people having one or more asthma exacerbations was significantly lower in the FeNO group compared to the
control group (odds ratio (OR) 0.60, 95% confidence interval (CI) 0.43 to 0.84). The number needed to treat to benefit (NNTB)
over 52 weeks was 12 (95% CI 8 to 32). Those in the FeNO group were also significantly more likely to have a lower exacerbation rate
than the controls (rate ratio 0.59, 95% CI 0.45 to 0.77). However, we did not find a difference between the groups for exacerbations
requiring hospitalisation (OR 0.14, 95% CI 0.01 to 2.67) or rescue oral corticosteroids (OR 0.86, 95% CI 0.50 to 1.48). There was
also no significant difference between groups for any of the secondary outcomes (FEV1, FeNO levels, symptoms scores, or inhaled
corticosteroid doses at final visit).
We considered three included studies that had inadequate blinding to have a high risk of bias. However, when these studies were
excluded from the meta-analysis, the difference between the groups for the primary outcomes (exacerbations) remained statistically
significant. The GRADE quality of the evidence ranged from moderate (for the outcome ’exacerbations’) to very low (for the outcome
’inhaled corticosteroid dose at final visit’) based on the lack of blinding and statistical heterogeneity. Six of the seven studies were
industry supported, but the company had no role in the study design or data analyses.
Authors’ conclusions
With new studies included since the last version of this review, which included adults and children, this updated meta-analysis in
adults with asthma showed that tailoring asthma medications based on FeNO levels (compared with primarily on clinical symptoms)
decreased the frequency of asthma exacerbations but did not impact on day-to-day clinical symptoms, end-of-study FeNO levels, or
inhaled corticosteroid dose. Thus, the universal use of FeNO to help guide therapy in adults with asthma cannot be advocated. As
the main benefit shown in the studies in this review was a reduction in asthma exacerbations, the intervention may be most useful in
adults who have frequent exacerbations. Further RCTs encompassing different asthma severity, ethnic groups in less affluent settings,
and taking into account different FeNO cutoffs are required.
P L A I N L A N G U A G E S U M M A R Y
Exhaled nitric oxide to guide asthma treatment for adults
Background
We examined whether exhaled nitric oxide (a marker in the breath which can show a type of lung inflammation) is useful in adjusting
asthma medications in adults in comparison to the usual ways that asthma medications are adjusted. Exhaled nitric oxide levels are
easily obtained by getting the person to breathe into a commercially available analyser.
Study characteristics
We included all randomised controlled trials that compared adjustment of asthma medications by usual clinical care (control group)
versus using exhaled nitric oxide. The participants included in the trials had asthma diagnosed as per relevant asthma guidelines.
The evidence is current to June 2016, when the searches were last completed.
We found seven studies in the searches. Of 1700 randomised participants, 1546 completed the trials. The studies varied in a few aspects
including duration, cutoff levels used for altering medications based on fractional exhaled nitric oxide (FeNO), and the way each study
defined exacerbations. The included studies ranged from 4 months to 12 months in duration. The FeNO cutoff values the studies
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used also varied. The levels used for decreasing medications ranged from 10 ppb to 25 ppb. Likewise, the levels used for increasing
medications ranged from 15 ppb to 35 ppb in the included studies. The majority of the studies were industry supported.
The mean ages of the participants ranged from 28 to 54 years old.
Key results
In this review involving 1700 adults with asthma, we found that guiding the dose of asthma medications based on exhaled nitric oxide
(compared to a control group) was beneficial in reducing the number of exacerbations (flare-ups) during the study period. However,
we did not find a difference between groups for other asthma outcomes that impact on day-to-day clinical symptoms, hospitalisations,
or inhaled steroid dose. Thus, using exhaled nitric oxide levels to adjust asthma therapy may reduce the risk of adults having an asthma
flare-up but did not impact on day-to-day symptoms.
Quality of the evidence
The quality of evidence ranged from moderate when comparing the two groups for the exacerbation outcomes, to very low when
comparing the groups for inhaled corticosteroid dose at final visit.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Tailoring asthma treatment using FeNO versus clinical symptoms
Patient or population: adults with asthma
Setting: outpat ient
Intervention: asthma treatment tailored on FeNO
Comparison: asthma treatment tailored on clinical symptoms
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with asthma treat-
ment tailored on clini-
cal symptoms* *
Risk with asthma treat-
ment tailored on FeNO
Number of participants
who had ≥ 1 exacerba-
tions over study period
Follow-up: range 18
weeks to 52 weeks
25 per 100 17 per 100
(13 to 22)
OR 0.60 (0.43 to 0.84) 1005
(5 RCTs)
⊕⊕⊕©
MODERATE1
-
Number of exacerba-
tions per 52 weeks (ex-
acerbation rates)
Follow-up: mean 52
weeks
The control group
ranged f rom 0.23 to 0.
9 exacerbat ions per 52
weeks
Rate ratio 0.59 (0.45 to
0.77)
- 842
(5 RCTs)
⊕⊕⊕©
MODERATE1
-
ICS dose at final visit
Follow-up: range 18
weeks to 52 weeks
The mean ICS dose
taken by the control
group at f inal visit was
659 mcg
The mean ICS dose
taken in the FeNO
groups was 17.01 lower
(101.75 lower to 67.72
more) 577 mcg
- 582
(4 RCTs)
⊕⊕©©
VERY LOW2,3
A random-ef fects sen-
sit ivity analysis gave a
very imprecise result :
MD -147.15 (95% CI -
380.85 to 86.56)
* The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
* * The control group risks were calculated as a mean of the scores or events in the control groups of the studies contribut ing to each analysis. We could not calculate a control
risk for the number of exacerbat ions per 52 weeks because we did not have information for each arm of the studies, just rat ios between them.
CI: conf idence interval; FeNO: f ract ional exhaled nitric oxide; ICS: inhaled cort icosteroids; M D: mean dif ference; OR: odds rat io; RCT: randomised controlled trial
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GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Two studies, Honkoop 2014 and Syk 2013, carrying 36%of the analysis weight, were at high risk of performance and detect ion
bias due to lack of blinding. There were several uncertaint ies across studies, part icularly with regard to the control of
select ion bias (one downgrade for risk of bias).
2Final inhaled cort icosteroid doses were quite varied, with one study having part icularly high doses (360 to 1282 in the control
groups and 423 to 740 in the FeNO groups). There was substant ial stat ist ical heterogeneity in the analysis (I2 = 82%; P =
0.0007). A random-ef fects sensit ivity analysis changed the result substant ially to MD -147.15 (95% CI -380.85 to 86.56) (one
downgrade for heterogeneity, one downgrade for imprecision).
3One study carrying 51% of the analysis weight, Syk 2013, was open labelled, which may have introduced bias (one downgrade
for risk of bias).
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B A C K G R O U N D
Description of the condition
Asthma guidelines aim to guide health practitioners to opti-
mise treatment for patients so as to minimise symptoms, opti-
mise lung function, and prevent acute exacerbations (BTS/SIGN
2014; GINA 2014; National Asthma Council 2014). Exacerba-
tions cause anxiety to patients and their families and are costly to
healthcare systems (Weiss 2001), which puts stress on healthcare
providers. Preventing exacerbations is thus an important compo-
nent formaintaining ideal asthma control. The second component
in asthma management is monitoring of asthma control (by sub-
jective and objective measures) (BTS/SIGN 2014; GINA 2014;
National Asthma Council 2014). Subjective measures usually in-
volve a series of questions used for clinical assessment, diary cards,
and quality of life questionnaires. Traditional objective methods
include peak flow, spirometry, and degree of airway hyper-respon-
siveness (Zacharasiewicz 2005). Newer, and arguably more sensi-
tive, methods include measurement of airway inflammation such
as airway cellularity in induced sputum or fractional exhaled nitric
oxide (FeNO).
In asthma, inflammation can be eosinophilic or neutrophilic
(Douwes 2002). Asthma management is arguably best tailored
in accordance with the type of airway inflammation, as corticos-
teroids are more beneficial in eosinophilic inflammation (Wardlaw
2000), and inhaled corticosteroids (ICS) reduce exacerbations and
improve symptoms and asthma control (Wardlaw 2000). There
are several ways to quantify airway eosinophilic inflammation,
such as determining the percentage of eosinophils in the sputum
and FeNO. FeNO correlates with other markers of asthma, for
example eosinophilia in induced sputum (Jatakanon 1998), and
bronchial reactivity in steroid-naive patients (Dupont 1998). In-
duced sputum and sputum analysis is labour intensive and not
widely available in non-research laboratories. Hypertonic saline,
which is used to induce sputum, may also temporarily increase
asthma symptoms.Measures of FeNO thus confer some advantage
over measurements of sputum eosinophils. However, FeNO does
not provide any data on non-eosinophilic inflammation, and the
equipment required to measure FeNO is relatively expensive.
Description of the intervention
The principle of asthmamanagement is based on a step-up or step-
down regimen of asthma medications to reduce airway inflam-
mation, control symptoms, and reduce exacerbations. Tailoring
of asthma medications in accordance to airway eosinophilic lev-
els may improve asthma control or reduce exacerbations or both.
FeNO levels can be measured using commercially available anal-
ysers. These analysers vary in several ways, including methods of
measurements (online or offline), complexity, their set-up, calibra-
tion procedures, sampling tube design, measuring chamber, and
the way expiratory flow is controlled (Muller 2005). Stationary
analysers measure FeNO by chemiluminescence, whilst portable
FeNO analysers measure FeNO using electrochemistry.
How the intervention might work
As FeNO is reflective of airway eosinophilia in some circum-
stances, FeNO can be considered as a biomarker. For asthma,
FeNO levels can potentially be used in adults with asthma to:
• monitor airway eosinophilia;
• verify the adherence to ICS; and
• predict upcoming asthma exacerbations.
Reduction of airway inflammation improves symptoms and
asthma control (Wardlaw 2000). Hence, the use of FeNO levels
to tailor asthma medications in adults with asthma may improve
asthma control or reduce exacerbations or both.
Why it is important to do this review
A Cochrane review has previously been published combining
adults and children in one review (Petsky 2009). Given the clinical
heterogeneity between children and adults with asthma, we un-
dertook separate reviews for children and adults for the updates.
Hence this is a new review, but is based on our previously pub-
lished review (Petsky 2009). This review focuses on adults, and
there will be a similar systematic review that includes only children
as participants (Petsky 2015b).
A systematic review evaluating the efficacy of tailoring asthma in-
terventions based on FeNO levels in comparison with not using
FeNO (that is the traditional reliance upon clinical symptoms
or following asthma guidelines with or without spirometry/peak
flow) will be useful to guide clinical practice in adults with asthma.
Using FeNO routinely in clinical practice adds to the burden of
asthma care and resource utilisation. On the other hand, routine
use of FeNO may improve asthma control and reduce exacerba-
tions and hospitalisations related to asthma.
O B J E C T I V E S
To evaluate the efficacy of tailoring asthma interventions based on
exhaled nitric oxide (FeNO) in comparison to not using FeNO,
that is management based on clinical symptoms (with or without
spirometry/peak flow) or asthma guidelines or both for asthma-
related outcomes in adults.
M E T H O D S
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Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) comparing ad-
justment of asthma medications based on exhaled nitric oxide lev-
els compared to those not using FeNO, that is management based
on clinical symptoms (with or without spirometry/peak flow) or
asthma guidelines or both. We included studies reported as full
text, those published as abstract only, and unpublished data.
Types of participants
We included adults with a diagnosis of asthma according to a
guideline-defined criteria.
We excluded participants with the following comorbidities/char-
acteristics: eosinophilic bronchitis, asthma related to an underly-
ing lungdisease such as bronchiectasis and chronic obstructive pul-
monary disease (COPD), or diagnostic categories such as ’cough
variant asthma’ and ’wheezy bronchitis’ where controversies exist.
Types of interventions
We included RCTs comparing adjustment of asthma medications
based on FeNO levels versus control groups where FeNO was not
used to adjust asthma medications. Control group interventions
may include use of clinical symptoms (with or without spirome-
try/peak flow) or asthma guidelines or both to guide adjustment
of asthma medications. We included studies in which other in-
terventions were used if all participants had equal access to such
interventions. We included studies of at least 12 weeks’ duration.
Types of outcome measures
Primary outcomes
Asthma exacerbations during follow-up, with the following defi-
nitions.
1. Number of participants who had one or more exacerbations
over the study period.
2. Number of exacerbations per 52 weeks (exacerbation rate).
3. Severe exacerbations requiring oral corticosteroids.
4. Severe exacerbation requiring hospitalisation.
Secondary outcomes
1. Objective measurements of asthma control (FEV1, peak
flow, airway hyper-responsiveness).
2. FeNO level.
3. Symptoms of asthma as reported in Asthma Control Test.
4. Symptoms of asthma as reported in asthma-related quality
of life questionnaire score (AQLQ).
5. Inhaled corticosteroid dose at final visit.
Reporting one or more of the outcomes listed here in the study
was not an inclusion criterion for the review.
Search methods for identification of studies
Electronic searches
We identified trials from the Cochrane Airways Group’s Spe-
cialised Register (CAGR), which is maintained by the Informa-
tion Specialist for the Group. The Register contains trial reports
identified through systematic searches of bibliographic databases
including the Cochrane Central Register of Controlled Trials
(CENTRAL), MEDLINE, EMBASE, CINAHL, AMED, and
PsycINFO, and handsearching of respiratory journals andmeeting
abstracts (please see Appendix 1 for further details). We searched
all records in the CAGR using the search strategy in Appendix 2.
We also conducted a search of Clinical-
Trials.gov (www.ClinicalTrials.gov) and the WHO trials portal (
www.who.int/ictrp/en/), using the search strategy in Appendix 3.
We searched all databases from their inception to June 2016, and
we imposed no restriction on language of publication.
Searching other resources
We checked reference lists of all primary studies and review arti-
cles for additional references.We searched relevant manufacturers’
websites for trial information.
We searched for errata or retractions from included studies pub-
lished in full text on PubMed (www.ncbi.nlm.nih.gov/pubmed)
and reported the date this was done within the review.
Data collection and analysis
Selection of studies
Two review authors (HP, KK) independently screened the titles
and abstracts of all the studies we identified as a result of the
search for inclusion and coded them as ’retrieve’ (eligible or poten-
tially eligible/unclear) or ’do not retrieve’. We then retrieved the
full-text study reports/publication, and two review authors (HP,
KK) independently screened the full text and identified studies
for inclusion, and identified and recorded reasons for exclusion
of the ineligible studies. We planned to resolve any disagreements
through discussion or, if required, by consulting a third review
author (AC). We identified and excluded duplicates and collated
multiple reports of the same study so that each study, rather than
each report, was the unit of interest in the review. We recorded the
selection process in sufficient detail to complete a PRISMA flow
diagram (Figure 1) and Characteristics of excluded studies table.
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Figure 1. Study flow diagram.
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Data extraction and management
We used a data collection form for study characteristics and out-
come data that had been piloted on at least one study in the re-
view. One review author (HP) extracted study characteristics from
included studies. We then extracted the following study charac-
teristics.
1. Methods: study design, total duration of study, details of
any ’run in’ period, number of study centres and location, study
setting, withdrawals, and date of study.
2. Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria, and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications, and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for trial, and notable conflicts of interest of
trial authors.
Two review authors (HP, KK) independently extracted outcome
data from included studies from the 2015 and 2016 searches.
We then noted in the Characteristics of included studies table if
outcome data were not reported in a useable way. We planned to
resolve disagreements by consensus or by involving a third review
author (AC). One review author (HP) transferred data into the
RevMan 2014 file.We double-checked that data had been entered
correctly by comparing the data presented in the systematic review
with the study reports. A second review author (KK) checked the
study characteristics for accuracy against the trial report.
Assessment of risk of bias in included studies
Two review authors (HP, KK) independently assessed risk of bias
for each study using the criteria outlined in theCochraneHandbook
for Systematic Reviews of Interventions (Higgins 2011).We planned
to resolve any disagreements by discussion or by involving another
review author (AC). We assessed the risk of bias according to the
following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We graded each potential source of bias as high, low, or unclear
and provided a quote from the study report together with a jus-
tification for our judgement in the ’Risk of bias’ table. We then
summarised the ’Risk of bias’ judgements across different studies
for each of the domains listed. We planned to judge blinding sep-
arately for different key outcomes where necessary (for example
for unblinded outcome assessment, risk of bias for all-cause mor-
tality may be very different than for a patient-reported pain scale).
Where information on risk of bias related to unpublished data or
correspondence with a trialist, we noted this in the ’Risk of bias’
table.
When considering treatment effects, we took into account the risk
of bias for the studies that contributed to that outcome.
Assessment of bias in conducting the systematic
review
We conducted the review according to this published protocol
and reported any deviations from it in the Differences between
protocol and review section of the systematic review.
Measures of treatment effect
We analysed dichotomous data as odds ratios and continuous data
as mean difference or standardised mean difference. We then en-
tered data presented as a scale with a consistent direction of effect.
We undertook meta-analyses only where it was meaningful, that is
if the treatments, participants, and the underlying clinical question
were similar enough for pooling to make sense.
We narratively described skewed data that was reported asmedians
and interquartile ranges.
Where multiple trial arms were reported in a single trial, we in-
cluded only the relevant arms. If two comparisons (for example
drug A versus placebo and drug B versus placebo) were combined
in the same meta-analysis, we halved the control group to avoid
double-counting.
Unit of analysis issues
For dichotomous data, we reported the proportion of participants
contributing to each outcome in comparison with the total num-
ber randomised. For rate ratios of common events whereby one
participant may havemore than one event, we used generic inverse
variance (GIV). We took the rate ratios from the published pa-
pers and calculated the standard errors from confidence intervals
(CI) or P values published in the papers. It was planned that for
cross-over studies, mean treatment differences were to be calcu-
lated from raw data, and variances extracted or imputed and en-
tered as fixed-effect GIV outcome, to provide summary weighted
differences and 95% CIs.
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Dealing with missing data
We contacted investigators or study sponsors to verify key study
characteristics and to obtain missing numerical outcome data
where possible (for example when a study was identified as ab-
stract only). Where this was not possible, and the missing data
were thought to introduce serious bias, we explored the impact of
including such studies in the overall assessment of results with a
sensitivity analysis.
Assessment of heterogeneity
We described and tested any heterogeneity between study results
to see if it reached statistical significance using a Chi2 test. We
planned to include the 95% CI estimated using a random-effects
model whenever there was concerns about statistical heterogene-
ity. Heterogeneity is considered significant when the P value is less
than 0.10 (Higgins 2011). We then used the I2 statistic to mea-
sure heterogeneity among the trials in each analysis. If we identi-
fied substantial heterogeneity, we reported it and explored possible
causes by prespecified subgroup analysis.
Assessment of reporting biases
As we were unable to pool more than 10 trials, we did not create
and examine a funnel plot to explore possible small-study and
publication biases.
Data synthesis
We included the results from studies that met the inclusion cri-
teria and reported any of the outcomes of interest in the subse-
quent meta-analyses. We calculated the summary weighted risk
ratio and 95% CI (fixed-effect model) (RevMan 2014). For rate
ratios of common events whereby one participant had more than
one event, we utilised GIV. We took the rate ratios from the pub-
lished papers and calculated the standard errors from CI or P val-
ues published in the papers. For cross-over studies, we planned to
calculate mean treatment differences from raw data, and extract
or impute variances and enter them as fixed-effect GIV, to provide
summary weighted differences and 95% CI. We calculated num-
ber needed to treat to benefit (NNTB) from the pooled odds ratio
and its 95% CI applied to a specified baseline risk using an online
calculator (Cates 2008). The outcome indices were assumed to be
normally distributed continuous variables so the mean difference
in outcomes could be estimated. If studies reported outcomes us-
ing different measurement scales, we estimated the standardised
mean difference.
’Summary of findings’ table
We created a ’Summary of findings’ table using the following out-
comes.
1. Number of participants who had one or more exacerbation
over the study period.
2. Number of exacerbations per 52 weeks.
3. Inhaled corticosteroid (ICS) dose at final visit.
The ’Summary of findings’ table in the previous combined review,
Petsky 2009, was amended to reflect the new data and restricted to
the inclusion criteria of this review. We used the five GRADE con-
siderations (study limitations, consistency of effect, imprecision,
indirectness, and publication bias) to assess the quality of a body
of evidence as it relates to the studies that contributed data to the
meta-analyses for the prespecified outcomes. We then used meth-
ods and recommendations described in Section 8.5 and Chapter
12 of the Cochrane Handbook for Systematic Reviews of Interven-
tions, Higgins 2011, using GRADEpro software. We justified all
decisions to down- or up-grade the quality of studies using foot-
notes, and we made comments to aid the reader’s understanding
of the review where necessary.
Subgroup analysis and investigation of heterogeneity
We planned subgroup analysis for the following.
1. Basis for adjustment of ICS in the control group (guideline-
driven monitoring versus non-guideline driven).
2. Use of spirometry or peak flow as an adjunctive monitoring
tool for adjustment of medications (versus non-use of spirometry
or peak flow).
3. Baseline ICS dose at commencement of intervention (low-
medium (< 800 mcg/day budesonide equivalent) versus high
dose (800 mcg/day or more budesonide equivalent)).
4. FeNO cutoffs for adjustment of medications (≤ 20 ppb
versus > 20 ppb).
5. FeNO cutoffs, based on presence of atopy.
Sensitivity analysis
We carried out the following sensitivity analyses.
1. Sensitivity analysis excluding studies with a high risk of bias
based on the ’Risk of bias’ assessment. Studies that did not have
adequate allocation concealment and sequence generation were
removed.
2. Variation in the inclusion criteria. Studies that included
adults not receiving ICS at recruitment were removed.
3. Differences in the medications used in the intervention and
comparison group. Studies that adjusted medications only for
one arm were removed.
4. Analysis that used the random-effects model.
5. Analysis that used ’strategy received’. Studies with hierarchy
management protocols that only considered use of steroids for
each step (i.e. without consideration for using montelukast or
long-acting beta-agonist or both at any point) were removed.
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R E S U L T S
Description of studies
Please see: Characteristics of included studies; Characteristics of
excluded studies; and Characteristics of ongoing studies.
Results of the search
The Cochrane Airways Group’s Specialised Register identified
1084 potentially relevant titles from the 2015 and 2016 searches
(Figure 1). We identified an additional 129 titles through searches
ofClinicalTrials.gov (www.ClinicalTrials.gov) and theWHOtrials
portal (www.who.int/ictrp/en/). After assessing the abstracts, we
obtained 30 papers for consideration after removal of duplicates.
We excluded 14 papers due to non-randomisation or treatment
not adjusted based on FeNO. Of the remaining 16 papers, seven
papers included adult participants, and nine were based on chil-
dren or adolescents, whichwill be presented in a separateCochrane
Review (Petsky 2015b).
Included studies
See Characteristics of included studies table.
We included seven studies involving a total of 1700 randomised
participants, of which 1546 completed the trial (Calhoun 2012;
Hashimoto 2011; Honkoop 2014; Powell 2011; Shaw 2007;
Smith 2005; Syk 2013). .
Study design
Six of the seven studies were parallel-group studies, and one used
cluster randomisation (Honkoop 2014). Five were multicentre
studies (Calhoun 2012; Hashimoto 2011; Honkoop 2014; Shaw
2007; Syk 2013); the remaining two were a dual-centre study, in
Powell 2011, and a single-centre study, in Smith 2005.
Two studies used a three-arm strategy to adjust inhaled corticos-
teroids (Calhoun 2012; Honkoop 2014). Calhoun et al’s strategy
arms were based on (i) National Heart, Lung, and Blood Insti-
tute guidelines (physician assessment-based adjustment (PABA)
group), (ii) measurement of exhaled nitric oxide (biomarker-based
adjustment (BBA)), or (iii) occurrence of symptoms prompting
rescue use of albuterol (symptom-based adjustment (SBA)). As the
PABA strategy utilised a national guideline, we used this group as
the control group and the BBA strategy as the intervention group.
Honkoop et al’s study also had three arms, which targeted (i)
partially controlled asthma (PCa), (ii) controlled asthma (Ca), or
(iii) FeNO-driven controlled asthma (FCa) (Honkoop 2014). The
controlled asthma strategy was used as the control group.
Despite Hashimoto et al’s study fitting the inclusion criteria
(Hashimoto 2011), we could not include some of their data in the
meta-analysis as the adjustments were based on the dose of oral
corticosteroids. Hashimoto 2011 used an internet-based manage-
ment tool comprised of (i) an electronic diary that included FeNO
measurement, (ii) treatment decision support for the participants,
and (iii) monitoring support by the study nurse.
Of the seven studies, two were double blind (Calhoun 2012;
Powell 2011), two were single blind (Shaw 2007; Smith 2005),
and three had no blinding (Hashimoto 2011;Honkoop 2014; Syk
2013).
The study duration varied, ranging from 4 months to 12 months
(Table 1). Each study defined exacerbations differently (Table 1).
Control group
Four of the seven studies utilised existing asthma guidelines to
adjust treatment in the control group (Calhoun 2012; Hashimoto
2011; Shaw 2007; Smith 2005). Two studies used the Asthma
Control Test (Honkoop 2014; Powell 2011). One study utilised a
combination of patient-reported symptoms, bronchodilator use,
physical examination, and spirometry results (Syk 2013) (Table
1).
FeNO strategy
The intervention arm in all seven studies, although primarily based
on FeNO level, differed in the cutoff for FeNO for change in
therapy. Syk 2013 was the only study utilising different cutoffs for
men and women. No studies took into account the presence of
atopy.
The FeNO cutoffs used for the studies are presented in Table 1.
Participants
The seven included studies used different inclusion criteria to re-
cruit participants. While all participants had to have asthma, how
the diagnosis was defined varied across the studies. Two stud-
ies defined asthma as per current guidelines (Hashimoto 2011;
Honkoop 2014). Six studies defined asthma as the current use of
asthma medications (Hashimoto 2011; Honkoop 2014; Powell
2011; Shaw 2007; Smith 2005; Syk 2013). Calhoun 2012 and
Syk 2013 based their definition of asthma on physician diagnosis
and positive airway hyper-responsiveness.
Outcomes
Four studies used asthma exacerbations or time-to-treatment fail-
ure as their primary outcome (Calhoun 2012; Powell 2011; Shaw
2007; Smith 2005). Each study defined exacerbations differently;
see Table 1. Hashimoto 2011 used AsthmaControl Questionnaire
and quality of life as their primary outcome. Honkoop 2014 used
quality-adjusted life years as their primary outcome. One study
used the change in Juniper Mini Asthma Quality of Life Ques-
tionnaire as their primary outcome (Syk 2013).
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Secondary outcomes also varied among the studies. Four studies
used spirometry (Calhoun 2012; Hashimoto 2011; Honkoop
2014; Syk 2013). Two studies included asthma exacerbations (
Hashimoto 2011; Honkoop 2014). In four studies asthma-related
quality of life was a secondary outcome (Calhoun 2012; Honkoop
2014; Powell 2011; Syk 2013), and three studies used dose of
inhaled corticosteroids (Shaw 2007; Smith 2005; Syk 2013).
Excluded studies
We excluded 24 studies; the reasons for the exclusion are presented
in theCharacteristics of excluded studies table. Themost common
reasons for exclusion were: not a randomised controlled trial (n
= 7), treatment not adjusted to FeNO (n = 6), and participants
were not adults (n = 9). We found a further study in abstract
form only (Duong-Quy 2015). We contacted the study author of
Duong-Quy 2015 in June 2016 and confirmed that the paper was
in preparation, therefore we judged this study as ongoing, to be
included in the next update.
Risk of bias in included studies
Full details of ’Risk of bias’ judgements can be found in the ’Risk of
bias’ section at the end of each Characteristics of included studies
table; a ’Risk of bias’ summary can be found in Figure 2. Overall,
the methodological quality of the included studies was high.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Generation of the randomisation sequence was described in three
studies (Hashimoto 2011; Powell 2011; Syk 2013), and unclear in
four studies (Calhoun 2012; Honkoop 2014; Shaw 2007; Smith
2005).We determined themethod of allocation concealment to be
adequate in three studies (Powell 2011; Shaw2007; Syk2013), and
unclear in three (Calhoun 2012; Honkoop 2014; Smith 2005).
However, we assessed one study as at high risk of bias for allocation
concealment (Hashimoto 2011).
Blinding
We deemed the risk associated with participant blinding to be low
when the study authors reported blinding of the assessors. These
were: “a third party provided advice on treatment decisions” and
“both arms of the study received the same follow-up including
measurements and tests”.
We considered risk of detection bias due to inadequate blinding
of outcome assessors to be high in three studies (Hashimoto 2011;
Honkoop 2014; Syk 2013), and unclear in one (Calhoun 2012),
as there was not enough information in the published protocol
and article. We judged three studies as having a low risk of bias
(Powell 2011; Shaw 2007; Smith 2005).
Incomplete outcome data
We assessed all studies as having a low risk of attrition bias.
Selective reporting
We considered three studies to have a low risk of reporting bias (
Hashimoto 2011;Honkoop 2014; Powell 2011), with all outcome
measures being reported. We judged three studies as unclear as
therewas not enough informationprovided in the published article
(Shaw 2007; Smith 2005; Syk 2013). We judged Calhoun 2012
as high risk as some of the secondary outcomes reported were not
correctly labelled or an incorrect analysis method was utilised.
Other potential sources of bias
Another source of bias was the success of obtaining FeNO levels at
each visit according to current guidelines. Six studies did not report
the success of obtaining FeNO at each time point (Calhoun 2012;
Hashimoto 2011; Honkoop 2014; Powell 2011; Smith 2005; Syk
2013). One study reported that they successfully obtained FeNO
at each visit (Shaw 2007).
Effects of interventions
See: Summary of findings for the main comparison Tailoring
asthma treatment using FeNO versus clinical symptoms
See Summary of findings for the main comparison for the main
comparisons.
Primary outcome: Asthma exacerbations
Four of the included studies used asthma exacerbations as their pri-
mary outcome (Calhoun 2012; Powell 2011; Shaw 2007; Smith
2005). See Table 1 for the definitions of exacerbations used. Five
studies reported a reduction in asthma exacerbations in the in-
tervention arm compared to the controls (treatment was based
primarily on clinical symptoms) (Honkoop 2014; Powell 2011;
Shaw 2007; Smith 2005; Syk 2013). For the various types of ex-
acerbations, data from the studies were combined into the meta-
analysis, as described below.
1.1 Number of participants who had one or more
exacerbations over the study period
Analysis 1.1
Hashimoto 2011 did not report on this outcome in the paper and
provided their data through correspondence (31 in FeNO group
and24 in control grouphadone ormore exacerbation).Combined
data from five studies showed that the number of participants
experiencing an exacerbation was significantly lower (P = 0.003)
in the FeNO group compared to the control (clinical symptom)
group over the study period; pooled odds ratio (OR) (fixed-effect
model) was OR 0.60 (95% confidence interval (CI) 0.43 to 0.84;
participants = 1005; studies = 5). There was no heterogeneity
among the studies; I2 = 13%. In the control group 149 out of 529
participants had at least one exacerbation over the study period,
compared to 116 out of 539 for the FeNO group. The number
needed to treat to benefit (NNTB) over 52 weeks was 12 (95%
CI 8 to 32).
1.2 Number of exacerbations per 52 weeks (exacerbation
rate)
Analysis 1.2
Combined data from five studies for this outcome also showed
a significant (P = 0.0001) reduction favouring the FeNO group;
rate ratio (RR) 0.59 (95% CI 0.45 to 0.77; participants = 842;
studies = 5). There was no statistical no heterogeneity among the
studies. The rate of exacerbation over the 52 weeks in the control
group ranged from 0.23 to 0.9.
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1.3 Severe exacerbations requiring oral corticosteroids
Analysis 1.3
Three studies reporting the use of oral corticosteroids could be
combined in a meta-analysis, showing no significant difference
between the groups (OR 0.86, 95% CI 0.50 to 1.48; participants
= 495; studies = 3; I2 = 0%).
1.4 Severe exacerbations requiring hospitalisation
Analysis 1.4
Five studies reported hospitalisations due to worsening of asthma
symptoms, but no participants were hospitalised in two studies
(Shaw 2007; Syk 2013). We did not include Hashimoto 2011
and Honkoop 2014 in the meta-analysis because they were cluster
randomised trials or due to the complexity of the intervention
used. In the Hashimoto 2011 study a total of nine people were
hospitalised (four in FeNO group and five in the control strategy).
The meta-analysis showed no significant difference between the
groups (OR0.14, 95%CI 0.01 to 2.67; participants = 488; studies
= 3; I2 = 0%).
Secondary outcomes
1.5 FEV1% predicted at final visit
Analysis 1.5
None of the included studies reported lung function, but we ob-
tained further data from the authors of four studies. There was
no significant difference between groups (mean difference (MD)
0.11, 95%CI -1.15 to 1.37; participants = 802; studies = 4). Shaw
et al reported that “there was no difference in FEV1 between the
groups over the duration of the study”, but no details were pro-
vided (Shaw 2007).
1.6 FeNO level (ppb) at final visit
Analysis 1.6
Five studies reported FeNO at final visit. The forest plot showed
no significant difference between the groups (standardised mean
difference (SMD) -0.00, 95%CI -0.16 to 0.15; participants = 668;
studies = 5; I2 = 0%). A random-effects analysis did not change
the results (SMD -0.00, 95%CI -0.16 to 0.15; participants = 668;
studies = 5).
1.7 Symptom score: Asthma Control Test
Analysis 1.7
Four studies reported Asthma Control Test results. Meta-analysis
showed no significant difference between groups (MD -0.08, 95%
CI -0.18 to 0.01; participants = 707; studies = 4; I2 = 0%).
1.8 Symptom score: Asthma-related quality of life
Analysis 1.8
Combined data from only two studies found no significant differ-
ence between groups for the AsthmaQuality of LifeQuestionnaire
(AQLQ) (MD 0.00, 95% CI -0.10 to 0.10; participants = 621;
studies = 2). Data from Hashimoto et al could not be included in
the meta-analysis, but reported that asthma-related quality of life
did not differ between the study groups (Hashimoto 2011).
1.9 Inhaled corticosteroids dose at final visit (budesonide
equivalent in mcg/day)
Analysis 1.9
There was no significant difference between the groups’ inhaled
corticosteroid (ICS) dose at final visit in the meta-analysis of four
studies (MD -17.01, 95% CI -101.75 to 67.72; participants =
582; studies = 4; I2 = 82%). There was significant statistical het-
erogeneity for this outcome, likely due to the large doses of steroids
used in one study (Smith 2005). Using random-effects, the dif-
ference between groups remained non-significant (MD -147.15
mcg/day, 95% CI -380.85 to 86.56).
Subgroup analysis and investigation of heterogeneity
1. Basis for adjustment of ICS in the control group
(guideline-driven monitoring versus non-guideline driven)
Analysis 1.10 and Analysis 1.11
Four of the included studies utilised guideline-driven monitoring
for the control group (Calhoun 2012; Hashimoto 2011; Shaw
2007; Smith 2005). In this subgroup, for the primary outcome
of exacerbation, the significant difference between groups was no
longer present. There were no differences between groups for the
number of participants who had one or more exacerbations (OR
0.87, 95% CI 0.47 to 1.61). The exacerbation rate was also not
significantly different between groups (RR 0.76, 95% CI 0.48 to
1.19; P = 0.23).
In the other three studies (Honkoop 2014; Powell 2011; Syk
2013), the adjustments were not guideline based. The meta-anal-
ysis of this subgroup significantly favoured the FeNO arm com-
pared to the control arm; the number of participants who had one
or more exacerbation (OR 0.51, 95% CI 0.34 to 0.76) and exac-
erbation rate between groups (RR 0.51, 95% CI 0.37 to 0.71).
When testing the subgroup differences, there was no difference
between the two subgroups for either outcome; Analysis 1.10 re-
ports no subgroup difference (P = 0.16). Likewise, Analysis 1.11
reports no difference (P = 0.17).
2. Use of spirometry or peak flow as an adjunctive
monitoring tool for adjustment of medications (versus non-
use of spirometry or peak flow)
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Two studies utilised spirometry when adjusting medications in the
control group (Honkoop 2014; Syk 2013), however as spirometry
was not the sole measurement for adjusting the medications, this
subgroup analysis could not be done. As per Table 1, Honkoop
2014 utilised the Asthma Control Test, 7-item version, which
includes spirometry, and Syk 2013 used patient-reported symp-
toms, short-acting beta-agonist use, physical review in addition to
spirometry.
3. Baseline ICS dose at commencement of intervention
(low-medium (< 800 mcg/day budesonide equivalent) versus
high dose (800 mcg/day or more budesonide equivalent))
In four studies (Calhoun 2012;Hashimoto 2011; Shaw 2007; Syk
2013), the median ICS dose at baseline was less than 800 mcg/
day budesonide equivalent. However, none of the studies analysed
their data based on baseline ICS dose, hence this subgroup analysis
could not be done.
4. FeNO cutoffs for adjustment of medications (≤ 20 ppb
versus > 20 ppb)
Five studies adjusted medications if FeNO levels were less than or
equal to 20 ppb, as described in Table 1 (Hashimoto 2011; Powell
2011; Shaw 2007; Smith 2005; Syk 2013). When considering
this in the subgroup analysis, the results were similar to the main
analyses.
For the primary outcomes of exacerbation, the FeNO group con-
tinued to have fewer exacerbations. By removing Honkoop 2014,
who adjusted medications when FeNO was greater than 20 ppb,
from the first outcome, the number of participants who had more
than one exacerbation over the study period, the difference re-
mained statistically different (OR 0.59, 95% CI 0.41 to 0.85; P =
0.004). Likewise, for the second primary outcome of exacerbation
rate, by removing Calhoun 2012 the FeNO group was favoured
(RR 0.57, 95% CI 0.43 to 0.75).
5. FeNO cutoffs, based on presence of atopy
None of the included studies considered atopy in their algorithm
for FeNO levels, therefore it was not possible to explore atopy
through subgroup analysis.
Sensitivity analyses
1. Excluding studies with a high risk of bias based on the
’Risk of bias’ assessment
Three of the included studies did not use blinding (Hashimoto
2011; Honkoop 2014; Syk 2013). However, removing the data
from these studies did not alter the results of the primary outcome
(exacerbations) found in the main analyses; the number of partic-
ipants who had one or more exacerbations over the study period
(OR 0.63, 95% CI 0.41 to 0.96; participants = 432; studies = 3)
and exacerbation rate (RR 0.61, 95%CI 0.45 to 0.82; participants
= 661; studies = 4).
2. Variation in the inclusion criteria
One study involving pregnant women only reported that not all
included adults were receiving ICS at recruitment (Powell 2011);
only 43.1% of control group and 41.1% of FeNO group were re-
ceiving ICS at baseline. Removing this study had little impact on
the effect estimate, but resulted in reduced precision for number
of participants with one or more exacerbations (OR 0.67, 95%
CI 0.44 to 1.01; P = 0.06; participants = 785; studies = 4). The
group differences for exacerbation rate remained significantly dif-
ferent between groups, favouring the FeNO group, but again with
reduced precision (RR 0.66, 95% CI 0.47 to 0.93; P = 0.02; par-
ticipants = 622; studies = 4).
3. Differences in the medications used in the intervention
and comparison group
No studies adjusted medications for only one arm, therefore we
did not undertake this planned sensitivity analysis.
4. Analysis used random-effects model
Using random-effects did not change the significant group differ-
ences for the primary outcomes, that is results favoured the FeNO
arm; the number of participants who had one or more exacer-
bations over the study period (OR 0.61, 95% CI 0.42 to 0.87;
participants = 1005; studies = 5) and exacerbation rate (RR 0.59,
95% CI 0.45 to 0.77; participants = 842; studies = 5).
5. Analysis by ’strategy received’
Four studies used hierarchymanagement protocols that were based
solely on the use of steroids for each step (that is without consider-
ation for using montelukast or long-acting beta-agonist or both at
any point) (Calhoun 2012; Hashimoto 2011; Shaw 2007; Smith
2005). Removing these studies from the analyses did not alter the
significant group differences found in the main analyses, which
favoured the FeNO arm; the number of participants who had one
or more exacerbation over the study period (OR 0.51, 95% CI
0.34 to 0.76; participants = 793; studies = 3) and exacerbation
rate (RR 0.51, 95% CI 0.37 to 0.71; participants = 401; studies
= 2).
D I S C U S S I O N
16Exhaled nitric oxide levels to guide treatment for adults with asthma (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Summary of main results
We found seven RCTs involving 1700 participants (1546 com-
pleted) that could be included in this review. The studies varied in
the FeNO levels and algorithms used. The duration of the studies
also differed, ranging from 4 to 12 months.
All studies reported our review’s primary outcome (exacerbation),
but the definition varied among the studies. We could combine
data from a maximum of five studies for the meta-analysis of the
different exacerbation types. The number of people having one
or more asthma exacerbation was significantly lower in the FeNO
group compared to the control group (OR 0.60, 95% CI 0.43
to 0.84). The NNTB over 52 weeks was 12 (95% CI 8 to 32).
Those in the FeNO group were also significantly more likely to
have a lower exacerbation rate than the controls (RR 0.59, 95%
CI 0.45 to 0.77). However, we did not find a difference between
the groups for exacerbations requiring hospitalisation (OR 0.14,
95% CI 0.01 to 2.67) or rescue oral corticosteroids (OR 0.86,
95% CI 0.50 to 1.48); only three studies contributed to the latter
outcome.
There was also no significant difference between groups for any of
the secondary outcomes (FEV1, FeNO levels, symptoms scores,
or ICS doses at final visit).
In the subgroup analyses, when the analyses were restricted to
the studies that utilised guidelines as the control group, the main
analyses for the primary outcome of exacerbations were altered,
with no difference seen between the FeNO and control groups
for the number of participants who had one or more exacerbation
(OR 0.87, 95% CI 0.47 to 1.61) or exacerbation rate (RR 0.76,
95% CI 0.48 to 1.19). There were no subgroup differences for
either primary outcome.
In the sensitivity analyses, the only changes from the primary out-
come analyses were seen when removing one study that included
pregnant participants not receiving ICS at the beginning of the
study (Powell 2011). The pooled effect size was similar, but there
was a loss of precision for both number of participants with one
or more exacerbation (OR 0.67, 95% CI 0.44 to 1.01; P = 0.06)
and exacerbation rate (RR 0.66, 95% CI 0.47 to 0.93; P = 0.02).
Overall completeness and applicability of
evidence
This review included seven studies, but the meta-analyses could
only include data from between two and five studies for the var-
ious outcomes, including our review’s primary outcome. The to-
tal number of participants for the various outcomes ranged from
488 (outcome: severe exacerbations requiring hospitalisation) to
1005 (outcome: number of participants who had one or more ex-
acerbations over the study period). Thus, although we contacted
authors of the studies, the completeness of the review was limited
by availability of data.
Despite two of the primary outcomes (’number of participants
who had one or more exacerbations over the study period’ and ’ex-
acerbation rate’) favouring the FeNO arm, there were no signifi-
cant group differences for severe exacerbations (requiring oral cor-
ticosteroids or hospitalisation) or for symptom scores and end-of-
study FEV1, FeNO, or ICS doses. In the subgroup analyses, when
considering only the studies that utilised guidelines for the con-
trol group (Calhoun 2012; Hashimoto 2011; Shaw 2007; Smith
2005), for the primary outcomes of exacerbations we found no
difference between the FeNO and control groups. However, un-
dertaking the sub-analysis resulted in a loss of power. In contrast,
when analyses were restricted to the studies that did not utilise
guidelines (Honkoop 2014; Powell 2011; Syk 2013), the differ-
ence in exacerbation rates between the FeNO and control groups
remained significant.
Hashimoto 2011 included participants with severe asthma who
had received long courses of oral corticosteroids (daily up to 46me-
dian months) and who were on high doses of ICS. Including this
study, which involved themost severe type of patients with asthma,
in the meta-analyses would have made some of the outcomes dif-
ficult to interpret, as it was designed to taper oral steroids, whereas
the other six included studies were adjusting inhaled asthma med-
ications. One study examined pregnant women (Powell 2011); as
it is unknown how FeNO levels are affected during pregnancy,
extrapolation of this review to pregnancy is limited. Furthermore,
less than 50% of women in this study were on ICS at baseline. As
the participants in the rest of the studies were on ICS, results of
this review should not be extrapolated to adults with asthma who
do not require daily ICS to control their symptoms.
One study used cluster randomisation with three treatment strate-
gies (Honkoop 2014), therefore not all data could be included in
the meta-analyses, as the raw data did not allow for the clustering
and inclusion of this data could have resulted in a unit-of-analysis
error.
The study setting also varied among the seven studies, with five
studies undertaken in primary care and two hospital-based. All
of the studies were undertaken in the last 11 years in affluent
countries: two in the Netherlands (Hashimoto 2011; Honkoop
2014), one in Sweden (Syk 2013), one in the US (Calhoun 2012),
one in Australia (Powell 2011), one in the UK (Shaw 2007), and
one inNewZealand (Smith 2005). Given the absence of data from
low- andmiddle-income countries, the findings of our review have
limited applicability in resource-poor settings.
Furthermore, as ethnicity likely influences FeNO levels in other-
wise healthy people (ATS FeNO 2005), the FeNO cutoff values
used to adjust themedications may be race or ethnicity dependent.
Some of the included studies were over 10 years old, and sub-
stantial research has been undertaken and published in the past
decade. Recently, Harnan et al conducted a systematic review and
economic evaluation for the National Institute for Health and
Care Excellence (NICE) to assess the diagnostic accuracy, clini-
cal effectiveness, and cost-effectiveness of three hand-held FeNO
analysers (Harnan 2015). The review, which included 27 studies,
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concluded that FeNO-guided management has the potential to be
cost-effective. However, the evidence for using FeNO for diagno-
sis and management was deemed inconclusive (Harnan 2015).
Lastly, asthma is a heterogenous condition, and there is increasing
appreciation of non-eosonophilic asthma and overlap syndromes
(withCOPD) (Karampitsakos 2016). As FeNO levels reflect lower
airway eosinophilia in steroid-naive people, the data from this
review is unlikely to be applicable to those with non-eosonophilic
asthma, smokers, overlap syndromes, and/or exacerbations that
are non-eosonophilic asthma.
Quality of the evidence
We summarised the evidence for the three main outcomes related
to exacerbations and ICS dose in the ’Summary of findings’ ta-
ble. Overall, we judged the quality of evidence to be very low
to moderate. Three studies were non-blinded (Hashimoto 2011;
Honkoop 2014; Syk 2013), which reduced our confidence in the
accuracy in these reported studies. The sensitivity analysis without
these studies indicated that the results from the blinded studies
still showed a reduction in the risk of exacerbations, but in view
of the different FeNO cutoffs used between the studies for adjust-
ment of maintenance treatment and the shortage of evidence from
trials that compared FeNO to guideline-adjusted treatment, we
downgraded the evidence in GRADE, as displayed in Summary
of findings for the main comparison.
The quality of evidence for the outcome of ICS dose at final visit
was very low. This could be due to variation in the ICS doses, with
one study having particularly high doses (360 to 1282 mcg in the
control groups and 423 to 740 mcg in the FeNO groups). There
was substantial statistical heterogeneity in the analysis (I2 = 82%;
P = 0.0007). We therefore downgraded this outcome by one for
heterogeneity and one for imprecision.
Potential biases in the review process
We are unaware of any biases in the review process. We used a
comprehensive search strategy and adhered to the protocol. Two
review authors (HP, KK) independently assessed the risk of bias.
We contacted the corresponding authors of all the studies for raw
data to include in the meta-analysis. KK and the review editor
(Christopher Cates) independently checked the data extraction,
’Risk of bias’ assessment, and downgrading decisions for the ’Sum-
mary of findings’ table in order to minimise the risk of bias in the
review process.
The inclusionofHashimoto 2011 in themeta-analyseswould have
introduced bias, as the strategy used was a complex intervention
of which FeNOwas only one part, however this study contributed
only to the meta-analysis of the final FeNO level (Analysis 1.6).
Agreements and disagreements with other
studies or reviews
This review updated a previous Cochrane review that included
paediatric and adult studies (Petsky 2009).We decided to separate
the reviews based on population ages and the increased clinical
trials on the subject. The original review included two adult studies
and four paediatric studies involving a total of 1010 participants
who completed the trials (Petsky 2009). This adult-only review
includes seven studies involving a total 1546 participants who
completed the trials. A separate paediatric review includes nine
studies with a total of 1390 children who completed the trials. The
paediatric Cochrane reviewhas yet to be completed to compare the
results with this Cochrane review involving adults (Petsky 2015b).
The results of Petsky 2009 differed from this current review, show-
ing no difference between the groups for the primary outcome of
exacerbations. Both adult papers included in the original review,
Shaw 2007 and Smith 2005, reported that their FeNO group ex-
perienced fewer exacerbations than the clinical-symptoms group,
but the differences were not significant. When the data were com-
bined, the number of participants who had one or more exacer-
bations over the study period did not differ (P = 0.76) between
the FeNO group and the clinical-symptoms group (pooled OR
0.85, 95% CI 0.30 to 2.43). However, the combined data from
five studies in this review showed that the number of participants
experiencing an exacerbation was significantly lower (P = 0.003)
in the FeNO group compared to the control (clinical-symptoms)
group over the study period; pooled OR (fixed-effect model) was
0.60 (95% CI 0.43 to 0.84) (Honkoop 2014; Powell 2011; Shaw
2007; Smith 2005; Syk 2013). There was no heterogeneity among
the studies (I2 = 13%). In the control group, 149 out of 529 par-
ticipants had at least one exacerbation over the study period, com-
pared to 116 out of 539 for the FeNO group. The NNTB over
52 weeks was 12 (95% CI 8 to 32) (Figure 3).
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Figure 3. In the control group, 25 people out of 100 had exacerbations over 52 weeks, compared to 17 (95%
CI 13 to 22) out of 100 for the active treatment group. NNTB 12 (95% CI 8 to 32).
ICS dose at final visit favoured the FeNO group in the original
Cochrane review (MD -450.03, 95% CI -676.73 to -222.34; P
< 0.0001) (Petsky 2009). The original review combined the data
from 98 participants allocated to the FeNO group. In this current
review, the combined data for the outcome of ICS dose at final
visit included 296 participants and did not favour either group
(MD -17.01, 95% CI -101.75 to 67.72; P = 0.69).
Essat et al published a systematic review on the utility of FeNO
for adjusting asthmamedications. The Essat 2016 review included
only six of the seven studies included in our Cochrane review. The
Essat 2016 paper also acknowledged the heterogeneity among the
studies and called for further research. In contrast to our findings
on the lack of difference between groups for ICS dose at final
visit, the Essat 2016 paper found a significant difference between
groups. In this Cochrane review, we used a standardised dose (that
is budesonide equivalent), but this conversion was not undertaken
in Essat 2016.
The Essat 2016 paper found a decrease in the FeNO group for
the outcome of ’all exacerbation and treatment failure rates’ with
the inclusion of three studies (RR 0.53, 95% CI 0.46 to 0.61,
P < 0.00001); our Cochrane review found similar results for this
outcome involving five studies (Analysis 1.1).
Another published systematic review, Lu 2015, was based on chil-
dren only and hence not comparable to our review, which evalu-
ated adults only. Likewise, Gomersal et al reported a systematic re-
view in children but did not undertake a meta-analysis comparing
FeNO-guided management with any other monitoring strategy
for children with asthma (Gomersal 2016). We will consider both
these papers, Essat 2016 and Gomersal 2016, in the Cochrane
review on children (Petsky 2015b).
No guidelines currently recommend the routine use of FeNO in
monitoring asthma. However, NICE guidelines are currently fo-
cusing on the impact and feasibility of implementing FeNO in a
diagnosis algorithm.
A U T H O R S ’ C O N C L U S I O N S
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Implications for practice
This review has demonstrated that tailoring asthma medications
based on exhaled nitric oxide (FeNO) levels significantly reduce
exacerbation numbers and rates, but found no significant differ-
ence between groups in hospitalisations or rescue oral corticos-
teroids courses. There were also no significant differences between
groups for any of our secondary outcomes: FEV1, ICS dosage,
FeNO levels, or symptoms scores. Additionally, none of the studies
reported a cost analysis. The use of FeNO to help guide therapy in
adults with asthma cannot thus be universally advocated, but may
be useful in some subpopulations. As the main benefit shown in
the studies in this review was a reduction in asthma exacerbations,
the intervention may be most useful in adults who have frequent
exacerbations.
Implications for research
Further double-blind, parallel-group RCTs are required. Studies
should also take into account various cutoffs for FeNO levels and
other significant influences on FeNO levels such as atopy, sex,
and ethnicity. A one-size-fits-all approach in relation to FeNO
levels may not be providing a clear picture. The effects of tailoring
asthma medications based on different levels of severity should
also be examined. Cost analyses and adverse events of inhaled
and oral corticosteroids would also provide additional important
information.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Calhoun 2012
Methods Randomised, parallel, 3-group, placebo-controlled, double-blinded multicentred trial
comparing 3 strategies to adjust inhaled corticosteroids in adults with mild to moderate
asthma. The 3 strategies were: a strategy based on National Heart, Lung, and Blood
Institute guidelines (PABA group), measurement of exhaled nitric oxide (BBA), or oc-
currence of symptoms prompting rescue use of albuterol (SBA group)
Participants 363 participants were enrolled with 342 randomised.
PABA group N = 114; mean age 34 (SD 12), 42 male, 72 female.
BBA group N = 115; mean age 35 (SD 11), 33 male, 82 female.
SBA group N = 113; mean age 36 (SD 12), 30 male, 83 female.
Participants were recruited with a concurrent Asthma Clinical Research Network trial,
but it was unclear as to where study visits occurred
Inclusion criteria: Physician diagnosis of asthma and either reversible airflow limitation
(≥ 12% improvement in FEV1 after 360 ug albuterol) or airway hyper-responsiveness
(provocative concentration of methacholine (< 8 mg/mL) causing a 20% drop in FEV1)
Interventions The adults with mild to moderate asthma on inhaled corticosteroids had their medica-
tions adjusted using 1 of 3 strategies:
• PABA group: a strategy based on National Heart, Lung, and Blood Institute
guidelines
• BBA group: measurement of exhaled nitric oxide
• SBA group: occurrence of symptoms prompting rescue use of albuterol
Outcomes Primary outcome: Time to first treatment failure, a clinically important worsening of
asthma
Secondary outcomes: Spirometry, albuterol reversibility, methacholine responsiveness,
sputum eosinophils, daytime and nighttime symptom and rescue beta-agonist diaries,
ACT, Asthma Symptom Utility Index, and AQLQ
Notes The control group used for the analysis was the PABA group, which utilised guidelines
Funding: The study was conducted with the support of the Institute for Translational
Sciences at the University of Texas Medical Branch, supported in part by a Clinical and
Translational Science Award from the National Center for Advancing Translational Sci-
ences, National Institutes of Health and by National Institutes of Health Grants awarded
by the National Heart, Lung, and Blood Institute. Teva Pharmaceuticals provided the
study drug and matching placebo. The National Heart, Lung, and Blood Institute had
no role in the design and conduct of the study; in the collection, analysis, and interpre-
tation of the data; or in the preparation, review, or approval of the manuscript
Risk of bias
Bias Authors’ judgement Support for judgement
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Calhoun 2012 (Continued)
Random sequence generation (selection
bias)
Unclear risk No description of how sequence was gen-
erated. Protocol from Asthma Clinical Re-
search Network also had no details of se-
quence generation
Allocation concealment (selection bias) Unclear risk Concealment not described in the publica-
tion. Protocol states that “the module set
up by DCC” will be used
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Study statesmultiblinded study and puffers
labelled A, B, C. However, it is unclear if
the puffers could be recognised by partic-
ipants or physicians or both, i.e. whether
they identical in appearance
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk As for blinding of participants, this is also
unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk Primary outcome was time to treatment
failure (asthma exacerbation) and sec-
ondary outcomes reported
Selective reporting (reporting bias) High risk Some secondary outcomes are reported in-
correctly, with label not correlatingwith the
results published
Other bias Unclear risk Days from school lost was reported, but
unsure of age used in the inclusion criteria.
The mean ages of the groups ranged from
34.2 to 36 years old
Hashimoto 2011
Methods Randomised, parallel, multicentred trial comparing 2 oral corticosteroid tapering strate-
gies. The 2 strategies were: internet-based monitoring system (internet strategy) or con-
ventional treatment based on GINA guidelines (conventional strategy)
Participants 150 people were assessed for eligibility, 95 participants were randomised. 89 participants
were included in the ITT analysis
Internet strategy N = 51, mean age 48.5 (SD 12.5), 23 male, 28 female
Conventional strategy N = 38, mean age 52.4 (SD 11.7), 18 male, 20 female
All participants were outpatients from2 tertiary academic hospitals or 4 large community
hospitals in the Netherlands
Inclusion criteria: Aged 18 to 75 years, diagnosis of severe refractory asthma as per ATS
minor and major criteria. Their asthma needed to be uncontrolled and being assessed
by a respiratory physician for at least 1 year, currently on oral corticosteroids, high doses
of ICS and long-acting bronchodilators
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Hashimoto 2011 (Continued)
Exclusion criteria: Smokers or non-smokers with history of > 15 pack-years. No internet
or mobile telephone
Interventions Monthly visits for 6 months with usual respiratory physician. Daily, participants reg-
istered their dose of oral corticosteroids, lung function, and FeNO before taking their
medications. Weekly, they completed the ACT. AQLQ completed at baseline and 3
monthly after this. Participants also registered every asthma event such as hospital visit,
deterioration in symptoms, and antibiotic use
Internet strategy: Had steroid dose adjusted based on the 3 components: electronic diary,
in-built algorithm (which includes FeNO levels), and monitoring support, e.g. coaching
by study nurse and monitoring data, which was entered
Conventional strategy: Their oral steroids down-titrated by the respiratory physician at
their monthly visit. The physicians treated the participants based on GINA guidelines
for patients with severe asthma
Outcomes Primary outcomes: Cumulative sparing of oral corticosteroids (actual cumulative dose
minus the expected cumulative dose), ACT, and AQLQ
Secondary outcomes: Global satisfaction scale, FEV1, number of exacerbations, and days
of hospitalisation
Notes No information provided on how successful the dailymonitoringwas and how compliant
participants were with daily tasks
Funding: This study was funded by the Netherlands Organisation for Health Research
and Development (ZonMw). Equipment for the analysis of nitric oxide was provided
by Aerocrine AB. The funding sources had no role in the study design, data collection,
analysis or interpretation, or in the decision to submit this article for publication
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated
Allocation concealment (selection bias) Unclear risk ’Unblinded after randomisation’; implies it
was concealed, but no details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Non blinded therefore high risk of detec-
tion bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk All outcome data reported
Selective reporting (reporting bias) Low risk All data reported
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Hashimoto 2011 (Continued)
Other bias Unclear risk Nil information provided in the pub-
lished article regarding success in obtaining
FeNO on each visit
Honkoop 2014
Methods 3-armed cluster randomised trial comparing 3 strategies aiming at either partially con-
trolled asthma (PCa), controlled asthma (Ca), or FeNO-driven controlled asthma (FCa)
. Cluster randomisation was performed at the general-practice level to prevent interven-
tion contamination within practices. Participants visited the practice every 3 months for
1 year and had their current medication assessed, asthma control assessed using ACT,
lung function and FeNO performed in the FCa group only
There was no blinding.
There were 31 dropouts prior to any interventions: 12 in PCa group, 6 in Ca group, and
13 in FCa group. In addition to these dropouts, 5 participants attended only once
Participants 3662 adults were assessed for eligibility, 647 of which were randomised
PCa group N = 219; mean age 39 (SD 9), 150 female, 69 males.
Ca group N = 203; mean age 40 (SD 10), 134 female, 69 males.
FCa group N = 189; mean age 39 (SD 9), 137 female, 62 males.
All participants were attending general practices in the regions of Amsterdam, Leiden,
and Nijmegen in the Netherlands
Inclusion criteria: Aged 18 to 50 years, doctor-diagnosed asthma according to Dutch
national guidelines, prescribed ICS for at least 3 months in the previous 12 months, and
asthma being managed in primary care
Exclusion criteria: Significant comorbidity (at the doctor’s discretion), inability to un-
derstand Dutch, and a prescription for oral corticosteroids in the previous month
Interventions At each visit the participant’s asthma control was assessed based on the ACT score as
controlled (≤ 0.75), partly controlled (0.75 to 1.5), or uncontrolled (> 1.5). Additionally,
participants in the FCa group were categorised based on FeNO levels as: low/absence
of airway inflammation ≤ 25 ppb, intermediate 26 to 50 ppb, and high/presence of
airway inflammation > 50 ppb. Treatment decisions were based on an algorithm for each
strategy, with an online decision support tool for implementing the strategy
Outcomes Primary outcome: societal costs per quality-adjusted life year (QALY) gained
Secondary outcomes: asthma control, asthma-related quality of life, number of days with
asthma-related limitations of activity, medication adherence, severe exacerbation rate,
lung function, FeNO value, and total medication use
Notes Control group used for analysis in this review was the controlled asthma (Ca) group
Funding: This study was supported by the Netherlands Organisation for Health Re-
search and Development and by the Netherlands Asthma Foundation. Aerocrine (Solna,
Sweden) provided 20 of a total of 40 fraction of exhaled nitric oxide meters for free
Risk of bias
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Honkoop 2014 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk An independent researcher randomly allo-
cated the general practice to 1 of the 3 treat-
ment strategies. Stratified according to re-
gion, urbanisation grade (rural versus ur-
ban), and practice nurse’s level of experi-
ence with asthma management (> 1 year or
< 1 year)
Allocation concealment (selection bias) Unclear risk Authors stated that “allocation was applied
to both the cluster and participant levels”.
However, it is unclear in the published ar-
ticle how this was achieved
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk All outcome data reported and analysed as
ITT
Selective reporting (reporting bias) Low risk All data presented and analysed as ITT
Other bias Unclear risk Nil information provided in the pub-
lished article regarding success in obtaining
FeNO on each visit
Powell 2011
Methods Randomised, parallel, double-blind controlled trial of FeNO-guided therapy in 2 an-
tenatal clinics. Expectant mothers were randomised to a FeNO-guided algorithm for
adjusting asthma therapy or a clinical-guideline algorithm. The randomisation was strat-
ified by maintenance budesonide dose (< 800 ug per day or > 800 ug per day)
The participant, research assistant, and investigators were blinded to the randomisation
group
There were 17 dropouts, 11 in the FeNO group and 6 in the control group
The women were reviewed monthly until delivery
Participants 242 women were recruited, of which 220 were randomised.
FeNO group N = 111; mean age 28 (range 27 to 29).
Control group N = 109; mean age 29 (range 28 to 30).
Attending antenatal clinics at 2 hospitals in New South Wales, Australia
Inclusion: Non-smoking pregnant women (aged > 18 years) with asthma using inhaled
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Powell 2011 (Continued)
therapy and attending the clinic. They were recruited at between 12 and 20 weeks’
gestation
Interventions The women were seen monthly until they delivered.
Clinical-symptom data, ACT score, present treatment, FeNO, and FEV1 were collected
at each visit. ACT score, FeNO levels, and current treatment were sent to the algorithm
keeper via facsimile for treatment recommendations
FeNO group: Sequential process, first FeNO concentrations used to adjust ICS dose,
and second ACT score used to adjust the LABA dose
Clinical group: Based on asthma control using Juniper ACT with cutoff points defined
as: well-controlled asthma (ACT < 0.75), partially controlled asthma (0.75 to 1.50), and
uncontrolled asthma (> 1.5)
Outcomes Primary outcome: Total number of asthma exacerbations (i.e. moderate and severe)
Secondary outcomes: QoL, asthma treatment, and fetal outcomes
Notes Funding: This study was funded by the National Health and Medical Research Council
of Australia
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was completed in blocks of
4 with an equal treatment allocation ratio
Allocation concealment (selection bias) Low risk A statistician used computer-generated
random number list for randomisation and
stratified by maintenance budesonide dose
at visit two ( < 800 ug per day or ≥ 800 ug
per day)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind. The use of an algorithm
keeper was not masked but was not directly
involved in the care or assessment of the
participant
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessment of asthma control was made
by investigators who were blinded to the
participant’s randomisation group. The al-
gorithm keeper received the ACT score,
FeNO level and current treatment via fac-
simile and applied the appropriate algo-
rithm and sent the treatment recommenda-
tion to the research assistant who informed
the participant
Incomplete outcome data (attrition bias)
All outcomes
Low risk All outcome data presented
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Powell 2011 (Continued)
Selective reporting (reporting bias) Low risk All data presented
Other bias Unclear risk Nil information provided in the pub-
lished article regarding success in obtaining
FeNO on each visit
Shaw 2007
Methods Randomised, single-blind controlled trial comparing exacerbation frequency and corti-
costeroid dosage in people whose asthma management was based on measurements of
FeNO to a control group where management was based on the British Thoracic Soci-
ety and Scottish Intercollegiate Guidelines Network treatment guidelines. Stratified by
baseline sputum eosinophil count, baseline rescue steroid course in last year
The participants were blinded to which group they were randomised to. At completion,
the participants were asked to record which randomisation group they thought they had
been assigned to
There were 15 dropouts, 6 in FeNO group and 9 in control group
The study ran for 12 months, and the participants were assessed 10 times
Participants 900 adults were contacted from general-practice registers, of which 118 were randomised
FeNO group N = 58; median age 50 (range 20 to 75), 27 males, 31 females
Control group N = 60; median age 52 (range 24 to 81), 27 males, 33 females
Attending a general practice in Leicester, UK.
Inclusion: > 18 years old, diagnosis of asthma and at least 1 prescription for anti-asthma
medication in the past 12 months
Exclusion: Current smokers, past smoking history of > 10 pack-years, or physician de-
termines that they are poorly compliant
Interventions Participants were seen at baseline, 2 weeks, month: 1, 2, 3, 4, 6, 8, 10, and 12
FEV1, FeNO, and Juniper asthma control score (JACS) were undertaken at each visit.
Methacholine challenge for sputum induction was undertaken at initial visit, 6 months,
and at completion of 12 months
In control group: Treatment was doubled if JACS > 1.57, and treatment halved if JACS
< 1.57 for 2 consecutive months
In FeNO group: When FeNO > 26 ppb, ICS was increased. If < 16 ppb, or < 26 ppb
on 2 separate occasions, treatment was decreased
Outcomes Primary outcome: Number of exacerbations.
Secondary outcome: Total ICS dose
Notes Funding: This study was supported by a grant from Asthma UK
Risk of bias
Bias Authors’ judgement Support for judgement
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Shaw 2007 (Continued)
Random sequence generation (selection
bias)
Unclear risk Insufficient information provided in pub-
lished article
Allocation concealment (selection bias) Low risk Randomisation was done by an inde-
pendent individual using minimisation
method, stratified by baseline sputum
eosinophil count, FeNO and rescue steroid
courses in the last year
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Single blind. Participants were assessed at
completion of study regarding the group
they thought they were assigned to, 49%
were unsure of which group they were
assigned. 33% correctly identified their
group, and 18% incorrectly identified their
group
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessment of asthma control was made by
investigators who were blinded to the par-
ticipant’s randomisation group. A separate
unblinded physician communicated to the
patient the correct treatment decision
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Unclear risk Insufficient information
Other bias Low risk Measurement of FeNO was successful on
every occasion
Smith 2005
Methods Randomised, placebo-controlled, single-blind study.Thiswas a 2-phase study,with phase
1 varying in duration (3 to 12months), where the dose of inhaled fluticasone was titrated
down in a stepwise manner until the optimal dose was deemed to have been achieved.
During phase 2 (12 months), optimal dose from phase 1 was continued, and therapy
was stepped up if asthma control was lost
Participants were blinded to which group they were assigned to
In phase 1 there were 16 dropouts, 13 during run-in and 3 during follow-up. Phase 2
had 5 dropouts during the 12 months
Participants 97 participants were randomised from 110 participants recruited, mean age of 44.8 years
(range 12 to 73) and 41 males, 69 females
FeNO group N = 46
Control group N = 48
Inclusion criteria: Inhaled corticosteroids for 6 months with no dose change in previous
6 weeks
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Smith 2005 (Continued)
Exclusion criteria: > 4 courses of oral prednisolone in previous 12 months, admission
to hospital in the last 6 months, any intensive care admissions, or cigarette smoking
(current or past history of > 10 pack-years)
Interventions Phase 1
Run-in period was for 6 weeks, after 2 weeks fluticasone 750 ug/day was commenced.
Visits were every 4 weeks until optimal dose was achieved
FeNO group: Adjustment of dose of ICS was based solely to keep FeNO < 15 ppb at
250 mL/sec
Control group: Dose adjustment based on asthma symptoms, nighttime waking, bron-
chodilator use, variation in PEFR and FEV1.
Phase 2
Visits every 2 months.
Upward adjustments made as per phase 1 but no downward adjustments would be made
from optimal dose
Outcomes Primary outcome: Frequency of exacerbation.
Secondary outcome: Mean daily dose of ICS
Notes Funding: This study was funded by the OtagoMedical Research Foundation, the Dean’s
Fund of the Dunedin School of Medicine, and a grant from the University of Otago.
Supplies of fluticasone were provided by GlaxoSmithKline (New Zealand). Equipment
for the analysis of nitric oxide in other studies was provided by Aerocrine
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information of randomisation
and sequence generation in published arti-
cle
Allocation concealment (selection bias) Unclear risk Insufficient information of randomisation
in published article
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Single blind. All treatment orders were ver-
ified independently by an investigator who
was blinded to treatment group
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Single blind. All treatment orders were ver-
ified independently by an investigator who
was blinded to treatment group
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data has been imputed using ap-
propriate methods
Selective reporting (reporting bias) Unclear risk Insufficient information provided in pub-
lished article
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Smith 2005 (Continued)
Other bias Unclear risk Nil information provided in published ar-
ticle regarding success of measuring FeNO
Syk 2013
Methods Multicentred, open-label, parallel RCT comparing a FeNO-guided strategy versus usual
care to adjust anti-inflammatory treatment to improve asthma-related QoL and asthma
symptoms whilst reducing asthma exacerbations in atopic participants with asthma in
primary care
Participants 165 participants completed the study from 187 randomised.
FeNO group N = 87, mean age 40.9 (SD 11.8), 48 males, 39 females
Control group N = 78, mean age 41.1 (SD 12.9), 46 males, 32 females
They attended 1 of 17 primary healthcare centres in 7 different autonomous healthcare
regions in Sweden
Inclusion criteria: aged 18 to 64 years, physician’s diagnosis of asthma, prescribed ICS
for > 6 months, confirmed IgE sensitisation to ≥ 1 major airborne perennial allergen
(dog, cat, or mite)
Exclusion criteria: pregnancy or breastfeeding, participation in another study, unstable
asthma, smokers, solely on montelukast or in combination with budesonide equivalent
dose 0 to 400 mcg
Interventions Participants were seen at enrolment, baseline (2 to 4 weeks later), month 2, month 4,
month 8, and month 12 (final visit)
FeNO, ACT, and registration of exacerbations were undertaken at each visit. mAQLQ
and GQLI were attended at baseline, month 4, and month 12 only
FeNO group: Treatment was adjusted according to a FeNO algorithm and 6 fixed
treatment steps
Control group: Treatment was adjusted according to usual care including patient-re-
ported symptoms, SABA use, physical examination, and lung functions results
Outcomes Primary outcome: change in mAQLQ score during the study.
Secondary outcome: changes in ACT score, exacerbation frequency, lung function,
generic QoL score, and overall medication use
Notes Funding: This study was funded by the Stockholm county council (PickUP), Centre
for Allergy Research, Karolinska Institute, and the Research Foundation of the Swedish
Asthma and Allergy Association. Support was also received from Aerocrine AB (NIOX
MINO instruments), Phadia AB (ImmunoCAP Rapid), Meda AB (Buventol Easyhaler)
, and MSD Sweden (small grant)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Prepared by the study coordinator outside
the primary health care centre. However,
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Syk 2013 (Continued)
unclear how sequence was generated
Allocation concealment (selection bias) Low risk Envelopes used in lottery randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label. FeNO analyser screen was cov-
ered for control group, therefore study staff
member nor participant knew the result.
However, the FeNO analyser screen was
not covered in FeNO group
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Regarding FeNO as the FeNO group was
not blinded to FeNO results which could
influence their symptom scores
Incomplete outcome data (attrition bias)
All outcomes
Low risk All outcome data reported
Selective reporting (reporting bias) Low risk The named outcomes were well reported
in the paper and the study protocol was
prospectively registered. Additional data
were provided by study authors
Other bias Unclear risk One of the authors (Alving K) was an em-
ployee and stock holder of Aerocrine (man-
ufacturer of FeNO analysers)
ACT: Asthma Control Test
AQLQ: Asthma Quality of Life Questionnaire
ATS: American Thoracic Society
BBA: biomarker-based adjustment
FeNO: fractional exhaled nitric oxide
FEV1: forced expiratory volume in 1 second
GINA: Global Initiative for Asthma
GQLI: Göteborg Quality of Life Instrument
ICS: inhaled corticosteroids
IgE: immunoglobulin E
ITT: intention-to-treat
LABA: long-acting beta-agonist
mAQLQ: mini-Asthma Quality of Life Questionnaire
QoL: quality of life
PABA: physician assessment-based adjustment
PEFR: peak expiratory flow rate
RCT: randomised controlled trial
SABA: short-acting beta-agonist
SBA: symptom-based adjustment
SD: standard deviation
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Anderson 2012 Excluded as treatment not adjusted according to FeNO. Randomised, cross-over trial evaluating the
dose response of ICS in people with asthma and elevated FeNO
de Jongste 2009 Excluded as study did not include adults but based instead in paediatric population. Included in paedi-
atric systematic review by same authors
Fritsch 2006 Excluded as study did not include adults but based instead in paediatric population. Included in paedi-
atric systematic review by same authors
Gelb 2006 Not a RCT, treatment not based on FeNO. Prospective study to assess FeNO and spirometry to predict
asthma exacerbations
Griese 2000 Not aRCT, treatment not based onFeNO. Prospective study to assess FeNO in comparison to symptoms
adjusted using clinical symptoms
Gruchalla 2009 Excluded as treatment not adjusted according to FeNO. Same dataset as paediatric included study
(Szefler 2008)
Jatakanon 1999 Excluded as treatment not based on FeNO. Randomised into 2 double-blind, placebo-controlled studies
(1 parallel study involving 3 groups receiving either budesonide 110 ug/day, budesonide 400 ug/day, or
placebo; the second was a cross-over randomised study to receive budesonide 1600 ug or placebo)
Jones 2001 Non-RCT. Observational study to determine if FeNO is useful in diagnosing and predicting loss of
asthma control. Participants had ICS withdrawn until loss of control or for a maximum of 6 weeks
Jones 2002 Excluded as treatment not based on FeNO. Double-blind, parallel-group, placebo-controlled trial of
50, 100, 200, or 500 ug budesonide per day
Kharitonov 1996 Non-RCT. Observational study of the effect of increasing and then reducing the dose of ICS on FeNO,
lung function, and symptoms in people with asthma
Kharitonov 2002 Excluded as treatment not adjusted according to FeNO. Double-blind, placebo-controlled, parallel-
group study of 100 or 400 ug budesonide or placebo in participants with mild asthma
Lim 1998 Excluded as treatment not adjusted according to FeNO. Randomised, longitudinal study monitoring
the effect of increasing anti-inflammatory medication or to continue unchanged using conventional
measures of lung function, symptom scores, medication usage, and peak expiratory flow rate variability
Malerba 2008 Excluded as non-randomised. Prospective observational study including 14 participants with asthma
who had asthma treatment adjusted based on sputum eosinophil counts and FeNO
Peirsman 2014 Excluded as study did not include adults but based instead in paediatric population. Included in paedi-
atric systematic review by same authors
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(Continued)
Petsky 2015a Excluded as study did not include adults but based instead in paediatric population. Included in paedi-
atric systematic review by same authors
Pijnenburg 2005 Excluded as study did not include adults but based instead in paediatric population. Included in paedi-
atric systematic review by same authors
Pike 2013 Excluded as study did not include adults but based instead in paediatric population. Included in paedi-
atric systematic review by same authors
Powell 2015 Excluded as reporting results regarding rhinitis from participants in an included study (Powell 2011)
Szefler 2008 Excluded as study did not include adults but based instead in paediatric population. Included in paedi-
atric systematic review by same authors
Verini 2010 Excluded as study did not include adults but based instead in paediatric population. Included in paedi-
atric systematic review by same authors
Voorend-van Bergen 2013 Excluded as study did not include adults but based instead in paediatric population. Included in paedi-
atric systematic review by same authors
Zacharasiewicz 2005 Non-RCT. Prospective and observation study in children using non-invasive measures (FeNO, induced
sputum, and exhaled breath condensate) to monitor airway inflammation to result in optimal treatment
FeNO: fractional exhaled nitric oxide
ICS: inhaled corticosteroids
RCT: randomised controlled trial
Characteristics of ongoing studies [ordered by study ID]
Duong-Quy 2015
Trial name or title Exhaled NO (FeNO)measurement used to determine asthma control, dose of inhaled corticosteroid and cost
in a developing country
Methods People with uncontrolled asthma with FeNO > 25 ppb were included in this study. They were classified into
3 groups according to the intervention used to determine therapy:
group 1 (Gr1): used GINA guidelines, group 2 (Gr2): used GINA plus FeNO, and group 3 (Gr3): used only
FeNO
Participants Unknown
Interventions Group 1 (Gr1): used GINA guidelines, Group 2 (Gr2): used GINA plus FeNO, and Group 3 (Gr3): used
only FeNO
Outcomes ICS dose, exacerbations, cost
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Duong-Quy 2015 (Continued)
Starting date Unknown
Contact information Sy Duong-Quy <sduongquy.jfvp@gmail.com>
Notes Prof Duong-Quy was contacted January 2016, when he stated that the article will be submitted in the near
future
FeNO: fractional exhaled nitric oxide
GINA: Global Initiative for Asthma
ICS: inhaled corticosteroids
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D A T A A N D A N A L Y S E S
Comparison 1. Asthma treatment tailored on FeNO versus clinical symptoms
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of participants who had
≥ 1 exacerbations over study
period
5 1005 Odds Ratio (Fixed, 95% CI) 0.60 [0.43, 0.84]
2 Number of exacerbations per 52
weeks (exacerbation rates)
5 842 Rate Ratio (Fixed, 95% CI) 0.59 [0.45, 0.77]
3 Severe exacerbations requiring
oral corticosteroids
3 495 Odds Ratio (M-H, Random, 95% CI) 0.86 [0.50, 1.48]
4 Severe exacerbations requiring
hospitalisation
3 488 Odds Ratio (M-H, Fixed, 95% CI) 0.14 [0.01, 2.67]
5 FEV1% pred at final visit 4 802 Mean Difference (Fixed, 95% CI) 0.11 [-1.15, 1.37]
6 FeNO level at final visit 5 668 Std. Mean Difference (IV, Fixed, 95% CI) -0.00 [-0.16, 0.15]
7 Symptom score as per Asthma
Control Test
4 707 Mean Difference (IV, Fixed, 95% CI) -0.08 [-0.18, 0.01]
8 Symptom score as per AQLQ 2 Mean Difference (Fixed, 95% CI) 0.00 [-0.10, 0.10]
9 ICS dose at final visit (microgram
per day)
4 582 Mean Difference (IV, Random, 95% CI) -147.15 [-380.85,
86.56]
10 Subgroup (control guideline
use): Number of participants
who had ≥ 1 exacerbations
over study period
5 Odds Ratio (Fixed, 95% CI) 0.60 [0.43, 0.84]
10.1 Guideline control 2 Odds Ratio (Fixed, 95% CI) 0.87 [0.47, 1.61]
10.2 Other control 3 Odds Ratio (Fixed, 95% CI) 0.51 [0.34, 0.76]
11 Subgroup (control guideline
use): Number of exacerbations
per 52 weeks (exacerbation
rates)
5 Rate Ratio (Fixed, 95% CI) 0.59 [0.45, 0.77]
11.1 Guideline control 3 Rate Ratio (Fixed, 95% CI) 0.76 [0.48, 1.19]
11.2 Other control 2 Rate Ratio (Fixed, 95% CI) 0.51 [0.37, 0.71]
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Analysis 1.1. Comparison 1 Asthma treatment tailored on FeNO versus clinical symptoms, Outcome 1
Number of participants who had ≥ 1 exacerbations over study period.
Review: Exhaled nitric oxide levels to guide treatment for adults with asthma
Comparison: 1 Asthma treatment tailored on FeNO versus clinical symptoms
Outcome: 1 Number of participants who had≥ 1 exacerbations over study period
Study or subgroup FeNO strategy Control strategy log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Honkoop 2014 189 203 -0.4463 (0.4546) 14.3 % 0.64 [ 0.26, 1.56 ]
Powell 2011 111 109 -0.7344 (0.2926) 34.4 % 0.48 [ 0.27, 0.85 ]
Shaw 2007 58 60 -0.5746 (0.4267) 16.2 % 0.56 [ 0.24, 1.30 ]
Smith 2005 46 48 0.3863 (0.4697) 13.4 % 1.47 [ 0.59, 3.69 ]
Syk 2013 93 88 -0.7244 (0.3679) 21.8 % 0.48 [ 0.24, 1.00 ]
Total (95% CI) 497 508 100.0 % 0.60 [ 0.43, 0.84 ]
Heterogeneity: Chi2 = 4.61, df = 4 (P = 0.33); I2 =13%
Test for overall effect: Z = 3.00 (P = 0.0027)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours FeNO strategy Favours control strategy
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Analysis 1.2. Comparison 1 Asthma treatment tailored on FeNO versus clinical symptoms, Outcome 2
Number of exacerbations per 52 weeks (exacerbation rates).
Review: Exhaled nitric oxide levels to guide treatment for adults with asthma
Comparison: 1 Asthma treatment tailored on FeNO versus clinical symptoms
Outcome: 2 Number of exacerbations per 52 weeks (exacerbation rates)
Study or subgroup FeNO strategy Control strategy log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Calhoun 2012 (1) 115 114 -0.1054 (0.4718) 8.4 % 0.90 [ 0.36, 2.27 ]
Powell 2011 111 109 -0.7012 (0.2157) 40.1 % 0.50 [ 0.32, 0.76 ]
Shaw 2007 58 60 -0.2357 (0.3028) 20.3 % 0.79 [ 0.44, 1.43 ]
Smith 2005 48 46 -0.6088 (0.5326) 6.6 % 0.54 [ 0.19, 1.55 ]
Syk 2013 (2) 93 88 -0.6218 (0.2754) 24.6 % 0.54 [ 0.31, 0.92 ]
Total (95% CI) 425 417 100.0 % 0.59 [ 0.45, 0.77 ]
Heterogeneity: Chi2 = 2.52, df = 4 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 3.89 (P = 0.00010)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours FeNO strategy Favours control strategy
(1) Reported as a Hazard ratio in the paper but appears to be a rate ratio (FeNO v Physician based assessment)
(2) Estimated from raw rates in Table V and P value from Poisson regression model
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Analysis 1.3. Comparison 1 Asthma treatment tailored on FeNO versus clinical symptoms, Outcome 3
Severe exacerbations requiring oral corticosteroids.
Review: Exhaled nitric oxide levels to guide treatment for adults with asthma
Comparison: 1 Asthma treatment tailored on FeNO versus clinical symptoms
Outcome: 3 Severe exacerbations requiring oral corticosteroids
Study or subgroup FeNO strategy Control strategy Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Powell 2011 9/111 13/109 37.3 % 0.65 [ 0.27, 1.59 ]
Smith 2005 13/46 15/48 38.1 % 0.87 [ 0.36, 2.10 ]
Syk 2013 8/93 6/88 24.6 % 1.29 [ 0.43, 3.87 ]
Total (95% CI) 250 245 100.0 % 0.86 [ 0.50, 1.48 ]
Total events: 30 (FeNO strategy), 34 (Control strategy)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.88, df = 2 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours FeNO strategy Favours Control strategy
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Analysis 1.4. Comparison 1 Asthma treatment tailored on FeNO versus clinical symptoms, Outcome 4
Severe exacerbations requiring hospitalisation.
Review: Exhaled nitric oxide levels to guide treatment for adults with asthma
Comparison: 1 Asthma treatment tailored on FeNO versus clinical symptoms
Outcome: 4 Severe exacerbations requiring hospitalisation
Study or subgroup FeNO strategy Control strategy Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Powell 2011 0/111 3/109 100.0 % 0.14 [ 0.01, 2.67 ]
Shaw 2007 0/52 0/51 Not estimable
Syk 2013 0/87 0/78 Not estimable
Total (95% CI) 250 238 100.0 % 0.14 [ 0.01, 2.67 ]
Total events: 0 (FeNO strategy), 3 (Control strategy)
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours FeNO strategy Favours Control strategy
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Analysis 1.5. Comparison 1 Asthma treatment tailored on FeNO versus clinical symptoms, Outcome 5
FEV1% pred at final visit.
Review: Exhaled nitric oxide levels to guide treatment for adults with asthma
Comparison: 1 Asthma treatment tailored on FeNO versus clinical symptoms
Outcome: 5 FEV1% pred at final visit
Study or subgroup FeNO strategy Control strategy Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
Honkoop 2014 189 203 0.04 (0.7347) 76.3 % 0.04 [ -1.40, 1.48 ]
Powell 2011 73 78 0.19 (1.902) 11.4 % 0.19 [ -3.54, 3.92 ]
Smith 2005 46 48 3.8 (4.2329) 2.3 % 3.80 [ -4.50, 12.10 ]
Syk 2013 87 78 -0.3 (2.0265) 10.0 % -0.30 [ -4.27, 3.67 ]
Total (95% CI) 395 407 100.0 % 0.11 [ -1.15, 1.37 ]
Heterogeneity: Chi2 = 0.81, df = 3 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.86)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours FeNO strategy Favours Control strategy
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Analysis 1.6. Comparison 1 Asthma treatment tailored on FeNO versus clinical symptoms, Outcome 6
FeNO level at final visit.
Review: Exhaled nitric oxide levels to guide treatment for adults with asthma
Comparison: 1 Asthma treatment tailored on FeNO versus clinical symptoms
Outcome: 6 FeNO level at final visit
Study or subgroup FeNO strategy Control strategy
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hashimoto 2011 51 58 (50.72) 38 58 (49.8) 13.1 % 0.0 [ -0.42, 0.42 ]
Powell 2011 110 18.62 (34.97) 107 17.44 (19.03) 32.7 % 0.04 [ -0.22, 0.31 ]
Shaw 2007 52 24.5 (14.42) 51 27 (17.85) 15.5 % -0.15 [ -0.54, 0.23 ]
Smith 2005 46 8.6 (4.04) 48 7.6 (4.64) 14.0 % 0.23 [ -0.18, 0.63 ]
Syk 2013 87 25 (14.5452) 78 27.1 (23.507) 24.7 % -0.11 [ -0.41, 0.20 ]
Total (95% CI) 346 322 100.0 % 0.00 [ -0.16, 0.15 ]
Heterogeneity: Chi2 = 2.38, df = 4 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours FeNO strategy Favours Control strategy
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Analysis 1.7. Comparison 1 Asthma treatment tailored on FeNO versus clinical symptoms, Outcome 7
Symptom score as per Asthma Control Test.
Review: Exhaled nitric oxide levels to guide treatment for adults with asthma
Comparison: 1 Asthma treatment tailored on FeNO versus clinical symptoms
Outcome: 7 Symptom score as per Asthma Control Test
Study or subgroup FeNO Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Calhoun 2012 115 0.68 (0.7335) 114 0.72 (0.7335) 27.0 % -0.04 [ -0.23, 0.15 ]
Powell 2011 111 0.5 (0.5) 109 0.6 (0.6) 45.6 % -0.10 [ -0.25, 0.05 ]
Shaw 2007 52 1.1 (0.72) 51 1.15 (0.71) 12.8 % -0.05 [ -0.33, 0.23 ]
Syk 2013 81 0.79 (0.814) 74 0.94 (0.8201) 14.7 % -0.15 [ -0.41, 0.11 ]
Total (95% CI) 359 348 100.0 % -0.08 [ -0.18, 0.01 ]
Heterogeneity: Chi2 = 0.56, df = 3 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 1.68 (P = 0.092)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours FeNO strategy Favours control strategy
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Analysis 1.8. Comparison 1 Asthma treatment tailored on FeNO versus clinical symptoms, Outcome 8
Symptom score as per AQLQ.
Review: Exhaled nitric oxide levels to guide treatment for adults with asthma
Comparison: 1 Asthma treatment tailored on FeNO versus clinical symptoms
Outcome: 8 Symptom score as per AQLQ
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
Calhoun 2012 0 (0.1122) 20.3 % 0.0 [ -0.22, 0.22 ]
Honkoop 2014 0.001 (0.0566) 79.7 % 0.00 [ -0.11, 0.11 ]
Total (95% CI) 100.0 % 0.00 [ -0.10, 0.10 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.99)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours FeNO strategy Favours Control strategy
Analysis 1.9. Comparison 1 Asthma treatment tailored on FeNO versus clinical symptoms, Outcome 9 ICS
dose at final visit (microgram per day).
Review: Exhaled nitric oxide levels to guide treatment for adults with asthma
Comparison: 1 Asthma treatment tailored on FeNO versus clinical symptoms
Outcome: 9 ICS dose at final visit (microgram per day)
Study or subgroup FeNO strategy Control strategy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Powell 2011 111 423.42 (561.65) 109 359.63 (516.24) 29.3 % 63.79 [ -78.72, 206.30 ]
Shaw 2007 52 557 (670.63) 51 895 (1035.51) 19.5 % -338.00 [ -675.63, -0.37 ]
Smith 2005 46 740 (720.63) 48 1282 (792.09) 21.0 % -542.00 [ -847.91, -236.09 ]
Syk 2013 87 586 (455.1236) 78 540 (319.3398) 30.3 % 46.00 [ -73.03, 165.03 ]
Total (95% CI) 296 286 100.0 % -147.15 [ -380.85, 86.56 ]
Heterogeneity: Tau2 = 43312.37; Chi2 = 17.10, df = 3 (P = 0.00067); I2 =82%
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Not applicable
-500 -250 0 250 500
Favours FeNO strategy Favours control strategy
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Analysis 1.10. Comparison 1 Asthma treatment tailored on FeNO versus clinical symptoms, Outcome 10
Subgroup (control guideline use): Number of participants who had ≥ 1 exacerbations over study period.
Review: Exhaled nitric oxide levels to guide treatment for adults with asthma
Comparison: 1 Asthma treatment tailored on FeNO versus clinical symptoms
Outcome: 10 Subgroup (control guideline use): Number of participants who had≥ 1 exacerbations over study period
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Guideline control
Shaw 2007 -0.5746 (0.4267) 16.2 % 0.56 [ 0.24, 1.30 ]
Smith 2005 0.3863 (0.4697) 13.4 % 1.47 [ 0.59, 3.69 ]
Subtotal (95% CI) 29.5 % 0.87 [ 0.47, 1.61 ]
Heterogeneity: Chi2 = 2.29, df = 1 (P = 0.13); I2 =56%
Test for overall effect: Z = 0.44 (P = 0.66)
2 Other control
Honkoop 2014 -0.4463 (0.4546) 14.3 % 0.64 [ 0.26, 1.56 ]
Powell 2011 -0.7344 (0.2926) 34.4 % 0.48 [ 0.27, 0.85 ]
Syk 2013 -0.7244 (0.3679) 21.8 % 0.48 [ 0.24, 1.00 ]
Subtotal (95% CI) 70.5 % 0.51 [ 0.34, 0.76 ]
Heterogeneity: Chi2 = 0.31, df = 2 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 3.29 (P = 0.0010)
Total (95% CI) 100.0 % 0.60 [ 0.43, 0.84 ]
Heterogeneity: Chi2 = 4.61, df = 4 (P = 0.33); I2 =13%
Test for overall effect: Z = 3.00 (P = 0.0027)
Test for subgroup differences: Chi2 = 2.01, df = 1 (P = 0.16), I2 =50%
0.01 0.1 1 10 100
Favours FeNO strategy Favours control strategy
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Analysis 1.11. Comparison 1 Asthma treatment tailored on FeNO versus clinical symptoms, Outcome 11
Subgroup (control guideline use): Number of exacerbations per 52 weeks (exacerbation rates).
Review: Exhaled nitric oxide levels to guide treatment for adults with asthma
Comparison: 1 Asthma treatment tailored on FeNO versus clinical symptoms
Outcome: 11 Subgroup (control guideline use): Number of exacerbations per 52 weeks (exacerbation rates)
Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Guideline control
Calhoun 2012 (1) -0.1054 (0.4718) 8.4 % 0.90 [ 0.36, 2.27 ]
Shaw 2007 -0.2357 (0.3028) 20.3 % 0.79 [ 0.44, 1.43 ]
Smith 2005 -0.6088 (0.5326) 6.6 % 0.54 [ 0.19, 1.55 ]
Subtotal (95% CI) 35.3 % 0.76 [ 0.48, 1.19 ]
Heterogeneity: Chi2 = 0.54, df = 2 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 1.19 (P = 0.23)
2 Other control
Powell 2011 -0.7012 (0.2157) 40.1 % 0.50 [ 0.32, 0.76 ]
Syk 2013 (2) -0.6218 (0.2754) 24.6 % 0.54 [ 0.31, 0.92 ]
Subtotal (95% CI) 64.7 % 0.51 [ 0.37, 0.71 ]
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 3.95 (P = 0.000078)
Total (95% CI) 100.0 % 0.59 [ 0.45, 0.77 ]
Heterogeneity: Chi2 = 2.52, df = 4 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 3.89 (P = 0.00010)
Test for subgroup differences: Chi2 = 1.93, df = 1 (P = 0.17), I2 =48%
0.1 0.2 0.5 1 2 5 10
Favours FeNO strategy Favours control strategy
(1) Reported as a Hazard ratio in the paper but appears to be a rate ratio (FeNO v Physician based assessment)
(2) Estimated from raw rates in Table V and P value from Poisson regression model
A D D I T I O N A L T A B L E S
Table 1. Included studies definitions
Study ID Exacerbation definition FeNO cutoff (ppb) Symptom strategy Duration
Calhoun 2012 Increased asthma symp-
toms resulting in use of
oral corticosteroids, in-
creased ICS, or additional
asthma medications
< 22 decrease
22 to 35 maintain
> 35 increase
Based on National Heart,
Lung, and Blood Institute
guidelines
9 months
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Table 1. Included studies definitions (Continued)
Hashimoto 2011 Decrease
in morning FEV1 > 10%
compared to mean FEV1
from week before, increase
in symptoms requiring in-
creased prednisolone > 10
mg/day, or course of an-
tibiotics, regardless of hos-
pitalisations
> +10 ppb & > 10% in-
crease
>+10ppb&≤ 10%main-
tain
minus≥10 &≤ 10 main-
tain
< -10 ppb decrease
Based on Global Initiative
forAsthma (GINA) guide-
lines for treatment of se-
vere asthma
6 months
Honkoop 2014 Severe exac-
erbations defined as hospi-
talisation, emergency de-
partment visit because of
asthma, or use of oral cor-
ticosteroids for 3 or more
days
< 25 decrease
25 to 50 no change
> 50 increase
Asthma Control Test, 7
items which includes lung
function
12 months
Powell 2011 Events for which the par-
ticipant soughtmedical at-
tention (unscheduled doc-
tor visit, emergency de-
partment visit, hospital
admission, or when oral
corticosteroids were used
to treat increase in asthma
symptoms)
< 16 decrease
16 to 29 maintain
> 29 increase
Asthma Control Test 4 months
Shaw 2007 Increasing asthma symp-
toms requiring course of
oral steroids or antibiotics
< 16 once or 16 to 26 sec-
ond decrease
> 26 increase
BTS and Asthma Control
Test
12 months
Smith 2005 Minor
exacerbation: global daily
asthma score of 2 on ≥ 2
consecutive days
Major
exacerbation: global daily
asthma score of 3 on ≥ 2
consecutive days
< 15 maintain
≥ 15 increase
(250 mL/sec)
GINA guidelines 12 months (Phase 2)
Syk 2013 Increasing symptoms re-
quiring a course of oral
corticosteroids
Women
< 19 decrease step
19 to 23 maintain
≥ 24 increase 1 step
≥ 30 increase 2 steps
Men
< 21 decrease step
Based on patient-reported
symptoms, SABA use,
physical examination, and
spirometry results
12 months
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Table 1. Included studies definitions (Continued)
21 to 25 maintain
≥ 26 increase 1 step
≥ 32 increase 2 steps
FeNO: fractional exhaled nitric oxide
FEV1: forced expiratory volume in 1 second
ICS: inhaled corticosteroids
SABA: short-acting beta-agonist
A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
CENTRAL (the Cochrane Library) Monthly
MEDLINE (Ovid) Weekly
EMBASE (Ovid) Weekly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
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Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
Asthma search
1. exp Asthma/
2. asthma$.mp.
3. (antiasthma$ or anti-asthma$).mp.
4. Respiratory Sounds/
5. wheez$.mp.
6. Bronchial Spasm/
7. bronchospas$.mp.
8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1-15
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
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8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.
Appendix 2. Search strategy to identify relevant trials from the CAGR
#1 AST:MISC1
#2 MeSH DESCRIPTOR Asthma Explode All
#3 asthma*:ti,ab
#4 #1 or #2 or #3
#5 MeSH DESCRIPTOR Nitric Oxide
#6 nitric* NEXT oxide*
#7 FeNO
#8 eNO
#9 “airway inflammation”
#10 “exhaled NO”
#11 biomarker*:ti,ab
#12 #5 or #6 or #7 or #8 or #9 or #10 or #11
#13 #4 and #12
[Note: in search line #1, MISC1 denotes the field in which the reference has been coded for condition, in this case, asthma]
Appendix 3. Search strategy to identify relevant trials from ClinicalTrials.gov andWHO trials portal
“exhaled nitric oxide” AND “asthma” AND “clinical trials”
C O N T R I B U T I O N S O F A U T H O R S
All review authors reviewed themanuscript.HP andKK extracted the data and performed the analysis. HP andACwrote themanuscript.
D E C L A R A T I O N S O F I N T E R E S T
Some of the review authors (HP, AC, CT) have conducted a randomised controlled trial in children on this subject.
KK: none known
S O U R C E S O F S U P P O R T
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authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS, or the Department of Health.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
After retrieving articles to include in the review that reported Asthma Control Test score, we added an additional secondary outcome:
symptoms of asthma as reported in Asthma Control Test.
We conducted a post hoc sensitivity analysis to remove the study that included pregnant women only (Powell 2011).
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